Related references
Note: Only part of the references are listed.CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer
Ilenia Migliaccio et al.
CANCER TREATMENT REVIEWS (2021)
Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
L. Malorni et al.
ANNALS OF ONCOLOGY (2021)
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Costanza Paoletti et al.
CLINICAL CANCER RESEARCH (2021)
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
Ilenia Migliaccio et al.
CANCERS (2021)
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
Amelia McCartney et al.
CLINICAL CANCER RESEARCH (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
Anna-Maria Larsson et al.
SCIENTIFIC REPORTS (2020)
Thymidine kinase 1 through the ages: a comprehensive review
Eliza E. Bitter et al.
CELL AND BIOSCIENCE (2020)
Plasma thymidine kinase 1 activity and outcome of ER+HER2-metastatic breast cancer patients treated with palbociclib and endocrine therapy
Luc Cabel et al.
BREAST CANCER RESEARCH (2020)
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)
Amelia McCartney et al.
EUROPEAN JOURNAL OF CANCER (2019)
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
L. Malorni et al.
ANNALS OF ONCOLOGY (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer
Ben O'Leary et al.
NATURE COMMUNICATIONS (2018)
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
Martina Bonechi et al.
Oncotarget (2018)
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci et al.
NPJ BREAST CANCER (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
Nusayba Bagegni et al.
BREAST CANCER RESEARCH (2017)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The AURORA initiative for metastatic breast cancer
D. Zardavas et al.
BRITISH JOURNAL OF CANCER (2014)
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Felipe Ades et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
J. Bjohle et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
Thymidine Kinase 1 Upregulation Is an Early Event in Breast Tumor Formation
Melissa M. Alegre et al.
JOURNAL OF ONCOLOGY (2012)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Thymidine kinase as a proliferative marker:: Clinical relevance in 1,692 primary breast cancer patients
P Broët et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
